RxDoctor Payments Data

Jose Lares, MD

Internal Medicine · Weslaco, TXNPI 1407902182

Payments from drug & device makers

$1,083in general payments, 2019–2025

Across 23 payments — averaging $47.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$310
  • AstraZeneca$188
  • Amgen$186
  • AbbVie$144
  • Argenx US, Inc.$125
  • Heartflow, Inc.$59
  • plus $72 from 3 others

What the payments were for

  • Food & beverage$1,083100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk6$310
AstraZeneca6$188
Amgen(2 entities)3$186
AbbVie(2 entities)2$144
Argenx US, Inc.1$125
Heartflow, Inc.1$59
Pfizer2$35
Shire North American Group Inc1$21
Johnson & Johnson1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,083 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$50,975
Medicare patients
159
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin164$194,796
OzempicSemaglutide138$162,695
MounjaroTirzepatide122$142,078
TradjentaLinagliptin93$107,343
TrulicityDulaglutide78$97,034
LinzessLinaclotide81$91,277
JanuviaSitagliptin Phosphate70$89,081
EliquisApixaban74$87,284
FarxigaDapagliflozin Propanediol80$87,181
XareltoRivaroxaban50$67,753
Synjardy XrEmpagliflozin/Metformin Hcl64$61,267
MyrbetriqMirabegron57$49,883
JanumetSitagliptin Phos/Metformin Hcl36$43,810
Tresiba Flextouch U-200Insulin Degludec38$41,430
EntrestoSacubitril/Valsartan38$41,097

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$310$162,695138 claims
AbbVieLinzess, Creon$144$102,13692 claims
PfizerEliquis$35$87,28474 claims
AstraZenecaFarxiga$188$87,18180 claims
Johnson & JohnsonXarelto$16$67,75350 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Weslaco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →